AR and prostate carcinoma: Accordingly, inhibition of MCP induced a dose-dependent decrease in the proliferation of hormone-responsive PCa cell lines, including LNCaP, VCaP, and C4-2, as well as the castrate-resistant ABL model, which maintains MPC protein expression during treatment with androgens and anti-androgens, but not in AR-negative prostate cancer cell lines PC-3 and DU145 [42].